Oncoheroes Obtains Exclusive Worldwide Oncology Pediatric Rights Of Dovitinib

por Oncoheroes Biosciences

2 years ago
dovitinib, Oncoheroes, Novartis, inhibidor pantirosina cinasa (TKI)

Oncoheroes Biosciences and Novartis have signed a worldwide, exclusive licensing agreement for dovitinib, a multi-tyrosine kinase inhibitor originally developed by Novartis. Under the terms of this ag...

Oncoheroes Announces Advancement in Pediatric Cancer Research

por Oncoheroes Biosciences

2 years ago
medulloblastoma, Oncoheroes

Oncoheroes Biosciences reveals the development of an innovative screening platform aimed at identifying potential drug candidates for medulloblastoma, a type of brain cancer prevalent in children

La FDA autoriza a Oncoheroes a iniciar dos ensayos clínicos de oncología pediátrica

por Oncoheroes Biosciences

3 years ago
volasertib, dovitinib, Oncoheroes

Oncoheroes Biosciences, Inc. ("Oncoheroes") ha anunciado hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha permitido a la biotecnológica con sede en Boston segu...

MEET A HERO: Grant, 2 year old at diagnosis

por Oncoheroes Biosciences

5 years ago
chemotherapy, healthcare facilities, childhood cancer, Oncoheroes

"Upside down," said Grant looking at himself in the mirror and pointing at his Spiderman T-shirt while standing up on a hospital bed. Grant Gossling was 2 years old when he was diagnosed with high-ris...

SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development and Commercialization of Oncology Therapeutics For Rare Cancers

por Oncoheroes Biosciences

5 years ago
Oncology Therapeutics, Rare Cancers, Oncoheroes, SHEPHERD, DELVE

SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for rare cancer patients, and Oncoheroes Biosciences, a biotech company focused on advancing new therapies for childho...